Supply updates

Last updated 4 September 2020

We commit to ensuring the quality, safety and reliable supply of our products. If the supply of our medicines or vaccines is disrupted in Australia we will publish details here.

At this unprecedented time, we are actively managing our global supply chains to minimise potential disruption, and we are monitoring the situation closely. We will put the needs of patients first at all times.

At present, with the exception of specific supply disruptions as outlined below, we have adequate stock in place in Australia.

We support the Government and Pharmacy industry's steps to introduce limits on dispensing and sales of prescription and over-the-counter medicines during the COVID-19 pandemic to ensure patients can access the medicines they need. 

 

DUAC Once Daily Gel

GSK is currently seeing a higher than anticipated demand for DUAC Once Daily Gel across Australia. We are experiencing a shortage of this medicine, and this is likely to remain in place until October 2020. Further information on this anticipated shortage is available on the TGA website. With alternative medicines available in the market, we do not anticipate an impact to patients.

 

DUODART

GSK is currently seeing a higher than anticipated demand for DUODART across Australia. We are experiencing a shortage of this medicine, and this is likely to remain in place until October 2020. Further information on this anticipated shortage is available on the TGA website. With alternative medicines available in the market, we do not anticipate an impact to patients.

 

Flixotide (fluticasone propionate) 0.5 mg/2 mL nebules

Flixotide 0.5 mg/2 mL nebules are currently unavailable due to high global demand. Supply in Australia is expected to recommence in February 2021.  Please consult your healthcare professional should you require an alternative.

 

Haemophilius influenzae type B (Hib) vaccine, HIBERIX

GSK is experiencing a supply constraint of our Haemophilius influenzae type B (Hib) vaccine, HIBERIX in the private market (Hiberix is not supplied on the National Immunisation Program). Healthcare professionals and patients may not be able to access HIBERIX vaccines temporarily until we return to supply. This supply constraint is caused by an unexpected increase in local demand in the first half of 2020. We expect to have an update available in December 2020.

 

Herpes zoster vaccine, Shingrix

GSK’s herpes zoster vaccine, Shingrix, is not available in Australia. There is currently no confirmed timing for the supply of Shingrix to Australia.

 

STIEVA-A 0.025% 0.25mg/g cream tube

GSK is currently seeing a higher than anticipated demand for STIEVA-A 0.025% 0.25mg/g cream tube across Australia. We are experiencing a shortage of this medicine, and this is likely to remain in place until November 2020. Further information on this anticipated shortage is available on the TGA website. With alternative medicines available in the market, we do not anticipate an impact to patients.

 

Ventolin inhalers

  • VENTOLIN INHALER CFC-Free Salbutamol 100 microgram (as sulfate) pressurised inhaler metered dose
  • VENTOLIN INHALER CFC-Free Salbutamol 100 microgram (as sulfate) pressurised inhaler metered dose (with counter)

From August 2020, an updated Ventolin (salbutamol) inhaler with a dose counter will be introduced gradually over a period of four to six months, while existing stock of VENTOLIN (without dose counter) continues to be sold in pharmacies.

While Australians may see limited availability of VENTOLIN with dose counter in the early months, the full transition is expected to be complete by early 2021. After this time, all VENTOLIN inhalers available will have a dose counter.

The inhaler with dose counter operates the same way for patients and contains the same medication and same dose. The only change is the integration of a dose counter which will allow patients to view the number of doses remaining in their inhalers.

The transition to the Ventolin (salbutamol) inhaler with dose counter is not expected to impact supply, though we continue to closely monitor the continuing peaks in demand which have occurred in the first half of 2020. 

We maintain good stock levels of Ventolin inhalers, however we will continue to monitor the situation to ensure supplies are distributed to where they are needed. Unprecedented and unpredictable high consumer demand for Ventolin (salbutamol) inhalers across Australia in the first half of 2020 may still periodically impact availability in some areas of the country at a pharmacy level.

 

Please visit the TGA website for ongoing updates to supply.

For more information on GSK's medicines or vaccines, please contact GSK medical information on 1800 033 109.